Company: INTS
Filing Date: 2025-03-28
Form Type: DRS
Source: 0001628279-25-000170
Chunk: 26

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-28
Form: DRS
Chunk 26
---
 on our Common Stock and we do not currently intend to pay any cash dividends on the Common Stock in the foreseeable future. We expect to retain all available funds and future earnings, if any, to fund the development and growth of our business. Any future determination to pay dividends, if any, on our Common Stock will be at the discretion of our board of directors and will depend on, among other factors, the terms of any outstanding preferred stock, our results of operations, financial condition, capital requirements and contractual restrictions.

<div align='center'>14

Confidential Treatment Requested by Intensity Therapeutics, Inc.</div>

#### Pursuant to 17 C.F.R. Section 200.83

### CAPITALIZATION
The following table sets forth our capitalization as December 31, 2024:

• on an actual basis; and

• on an as adjusted basis, after giving effect to the sale of shares of our Common Stock in this offering based on an assumed public offering price of $ per share, which was the last reported sale price of our Common Stock on Nasdaq on , 2025, and after deducting estimated Placement Agents’ fees and estimated offering expenses payable by us and assuming no sale of any Pre-Funded Warrants in this offering and no exercise of the Common Warrants issued in connection with this offering.

You should read this table together with our financial statements and the related notes thereto, as well as “ Management’s Discussion and Analysis of Financial Condition and Results of Operations ” and the other financial information, incorporated by reference in this prospectus from our SEC filings, including our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q or our Current Reports on Form 8-K. The as adjusted information presented in the capitalization table below is unaudited.

|                                                                                                                                                              |     | December 31, 2024                              |         |     |             |
|:-------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:-----------------------------------------------|--------:|:----|:------------|
|                                                                                                                                                              |     | -in thousands, except share and par value data |         |     |             |
|                                                                                                                                                              |     | Actual                                         |         |     | As Adjusted |
| Cash and cash equivalents                                                                                                                                    |     | $                                              |   2,590 |     |             |
| Shareholders’ equity                                                                                                                                         |     |                                                |         |     |             |
| Common Stock; $0.0001 par value, 150,000,000 shares authorized, 15